Introduction
============

Infections caused by multidrug-resistant Gram-positive pathogens, such as methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin-resistant enterococci (VRE), usually result in significant morbidity and mortality. According to the Taiwan surveillance data, the proportion of VRE among all enterococcal isolates causing nosocomial infections in intensive care units (ICUs) in medical centers increased from 12.4% in 2007 to 42.9% in 2016, and the proportion of MRSA among all staphylococcus isolates decreased from 83.7% in 2007 to 68.5% in 2016.[@b1-tcrm-14-493] However, therapeutic options for these resistant pathogens are limited, particularly for strains with high minimum inhibitory concentration.

Daptomycin is a lipopeptide antibiotic approved for the treatment of Gram-positive pathogens-associated complicated skin infections and bacteremia. The recommended dose is 4--6 mg/kg once daily by manufacturer information. The optimal dose for certain difficult-to-treat infections has not been defined. Because of its characteristic of concentration-dependent killing and dose-dependent post-antibiotic effect, recent guidelines advocated increasing daptomycin dose to 8--10 mg/kg once daily to optimize therapy for infective endocarditis.[@b2-tcrm-14-493],[@b3-tcrm-14-493] Indeed, a multicenter prospective cohort study conducted at our hospital system revealed that high-dose daptomycin (≥9 mg/kg/day) was associated with better survival rates in the treatment of VRE bacteremia.[@b4-tcrm-14-493] In the present study, we adapted the same criteria and defined daptomycin use of ≥9 mg/kg/day as the high dose, and that \<9 mg/kg/day was defined as the standard dose.

The major safety concern with daptomycin is the elevation of creatine kinase (CK) level, which may progress to rhabdomyolysis. Although the incidence of CK elevation was quite low, few studies examined the safety of daptomycin in patients with renal impairment, and most of the study populations were treated with the standard dose of \<9 mg/kg.[@b5-tcrm-14-493]--[@b8-tcrm-14-493] Accumulation of daptomycin was documented in patients with renal impairment due to decreasing renal clearance,[@b9-tcrm-14-493] and the previous study showed that higher daptomycin trough concentration (\>24.3 mg/L) was associated with a higher probability of CK elevation. Therefore, the primary aim of this study was to investigate the safety of daptomycin use in this fragile population.

Methods
=======

Study design and setting
------------------------

This was a retrospective single-center study conducted at National Taiwan University Hospital (NTUH), a 2600-bed tertiary medical center located in Taipei City, Taiwan. The Research Ethics Committee of NTUH approved the study protocol (201503064RINB). The requirement for informed consent was waived because of the retrospective nature of the study and using data from which the patients' identification information had been removed.

Patient inclusion and data collection
-------------------------------------

We retrospectively reviewed the electronic medical records for data collection. All adult patients treated with daptomycin at NTUH from January 1, 2013, to June 30, 2016, were included if they had renal impairment. Patients were excluded if the medical records were incomplete or the treatment duration of daptomycin was \<3 days. A standardized case report form was used to collect data including demographic characteristics (age, gender, body weight, body height, body mass index \[BMI\]), creatinine clearance (CL~Cr~), type of renal replacement therapy, concurrent use of medication (statins, fibrates, and colchicine), and use of antimicrobial agents, isolated pathogens, indications for daptomycin, dosage, dosing frequency, treatment duration and response, frequency of CK monitoring, and CK level.

Definition
----------

Renal impairment was defined as CL~Cr~ \<30 mL/min or receiving renal replacement therapy. The Cockcroft--Gault equation was used to calculate CL~Cr~.[@b10-tcrm-14-493] Patients with a BMI ≥30 were considered obese according to WHO definition. High-dose daptomycin therapy was defined as doses of daptomycin ≥9 mg/kg, and doses \<9 mg/kg were defined as the standard dose. Daptomycin treatment success was defined by resolving clinical signs and symptoms, no additional antibiotic therapy, and eradication of the causative pathogen documented at the end of daptomycin therapy. Elevated CK level was defined as CK level \>1,000 U/L during daptomycin therapy. Evaluation of daptomycin-related CK elevation was based on the judgment of two clinical pharmacists who retrospectively reviewed the medical records. Surgery, trauma, and seizure attack during daptomycin therapy were considered the possible causes for CK elevation, and subjects were excluded for safety analysis if these conditions were attributed to the main causes for CK elevation according to the clinical pharmacists' judgment. Patients with no record of CK level during the treatment course were considered as no CK elevation. The primary outcome was to compare the percentages of patients with elevated CK between the groups receiving high doses vs standard doses of daptomycin.

Statistical analysis
--------------------

Data were described as means ± SDs or numbers with percentages. The Mann--Whitney *U*-test was used for continuous data; either chi-square or Fisher's exact test was used for categorical data. A *P*-value ≤0.05 was considered statistically significant. Multivariate logistic regression was performed to identify the factors associated with CK elevation. Explanatory variables were included in the multivariate analysis if they showed significance in univariate analysis (*P*\<0.2). The statistical analysis was performed by Microsoft Office Excel 2003 (Microsoft, Redmond, WA, USA) and SPSS 18 (SPSS Inc, Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

From January 1, 2013, through June 30, 2016, 365 patients treated with daptomycin were screened, and 164 patients met the inclusion criteria. The demographic characteristics of the patients included are listed in [Table 1](#t1-tcrm-14-493){ref-type="table"}. Patients had a mean age of 68.1±16.5 years, and 62.2% were \>65 years old. Eighty-seven patients (53.0%) were male, and 10 patients (6%) were obese. One hundred and seven patients (65.2%) were admitted in ICU. There were 114 patients (69.5%) who received concurrent renal replacement therapy during the treatment course. Before the use of daptomycin, 105 (64%) patients received other antibiotic treatments. More patients in high-dose group had been treated with other antibiotic before daptomycin than those in the standard-dose group (81.1% vs 59.1%, respectively; *P*=0.014). Significant differences in body weight existed between high- and standard-dose groups (*P*\<0.001); there was only one obese patient in the high-dose group, whereas nine patients were obese in the standard-dose group.

Antimicrobial therapy and microbiological results
-------------------------------------------------

The most documented type of infection treated with daptomycin was bloodstream infection (55.5%), followed by urinary tract infection (12.8%) and intra-abdominal infection (11.0%). VRE was the most frequently isolated pathogen (61.3%) among the 142 patients with documented pathogens. The mean daptomycin dose was 8.0±2.3 mg/kg, and 37 (22.6%) patients received the high dose (≥9 mg/kg) of daptomycin therapy. The dosing frequency of every 48 h was prescribed in 129 patients (78.7%). The median treatment duration was 12.5 (11) days. One hundred and thirty-two patients had concurrent antibiotic therapy including β-lactams (78%), rifampin (7.3%), co-trimoxazole (7.3%), and gentamicin (1.8%). In our study, obese patients received a significantly lower dose of daptomycin than nonobese patients (6.8±1.7 vs 8.1±2.3 mg/kg, *P*=0.027).

Treatment safety and response
-----------------------------

CK levels were measured in 108 (65.9%) patients. Six patients had significant CK elevation during daptomycin therapy, and three of them had muscle symptoms, as detailed in [Table 2](#t2-tcrm-14-493){ref-type="table"}. Recovery from CK elevation was observed in all patients after the discontinuation of daptomycin treatment. We also found a significantly higher incidence rate of CK elevation in the high-dose group compared with that in the standard-dose group (10.8% vs 1.6%, *P*=0.025; [Table 3](#t3-tcrm-14-493){ref-type="table"}). Patients with CK elevation received a significantly higher average dose of daptomycin than those who did not have elevated CK (9.3±1.2 vs 7.9±2.3 mg/kg, *P*=0.034). For multivariate analysis, ICU admission, acute kidney injury, septic arthritis, and high dose of daptomycin use were put in the final model, and the result confirmed that high-dose daptomycin was the only significant factor associated with CK elevation (odds ratio 7.46; 95% CI, 1.22--45.69; *P*=0.03.)

There was no significant difference in the incidence rate of CK elevation between patients with different dosing frequency or the concurrent use of statins, fibrates, or colchicine. The overall treatment success rate was 51.6% in the 91 patients with bloodstream infection. Among patients with monomicrobial bloodstream infections, the treatment success rates were 60.9% for MRSA and 40.6% for VRE, respectively.

Discussion
==========

This study explored the important safety issue of using high doses of daptomycin in patients with renal impairment. Almost 70% of our patients were under renal replacement therapy during daptomycin treatment course. In patients with renal impairment, especially those treated with hemodialysis, the administration of various antimicrobial agents remains a challenging job. The recommended dosing regimen of daptomycin for the patients with CL~Cr~ \<30 mL/min or under renal replacement therapy is 4--6 mg/kg every 48 h based on approved indications.[@b11-tcrm-14-493] However, there may be a discrepancy between the approved dosing regimen and the hemodialysis schedule. Daptomycin can be removed by hemodialysis, and dosing regimen to give the doses three times a week coinciding with each dialysis session was proposed.[@b12-tcrm-14-493] Twenty-two patients in our study were treated with daptomycin according to this thrice-weekly dosing. A previous research has shown that the pharmacokinetics of daptomycin was linear with doses up to 12 mg/kg in healthy volunteers.[@b13-tcrm-14-493] Compared with healthy subjects, exposure to daptomycin was increased two- to threefold in patients with severe renal impairment and those on hemodialysis.[@b14-tcrm-14-493] Daptomycin accumulated in patients with renal impairment may result in higher trough levels and therefore increase the probability of CK elevation.[@b15-tcrm-14-493] As recommended by the prescribing information, CK level should be monitored at least once per week during daptomycin treatment. In adult patients with renal impairment, both renal function and CK should be monitored more frequently than once a week.[@b9-tcrm-14-493] A pooled analysis of CORE (Cubicin^®^ Outcomes Registry and Experience) and EUCORE (European Cubicin Outcomes Registry and Experience) revealed that blood CK levels were measured only in 43.5% of patients during daptomycin therapy.[@b16-tcrm-14-493] Monitoring of CK level was performed in 65.9% of patients in our study. In previous studies, the incidence rate of CK elevation due to daptomycin was considered low (1.9%--2.0%, CK level \>5× the normal upper limit),[@b5-tcrm-14-493],[@b6-tcrm-14-493],[@b16-tcrm-14-493] and there was no significant difference of CK elevation rate between different dosage groups.[@b16-tcrm-14-493] This low incidence rate might be explained by the low percentage of patients with renal impairement[@b5-tcrm-14-493],[@b16-tcrm-14-493] or a relatively lower dose of daptomycin.[@b6-tcrm-14-493]

Although the rate of CK monitoring in our study was greater than that in previous studies, 34.1% of our patients did not have CK level for assessment, and we assumed these patients did not have CK elevation. Comparisons between patients with or without CK measurement are listed in [Table 4](#t4-tcrm-14-493){ref-type="table"}. Significantly different factors between two groups were types of renal failure, treatment duration, seizure or surgery during therapy, and concurrent antibiotic therapy with gentamicin. It is reasonable to monitor CK if treatment duration is longer and patients had seizure or surgery, which are the well-known etiologies for CK elevation. Patients receiving dialysis may lead to more drug accumulation, which could increase the risk of CK elevation. Therefore, it would be reasonable to assume that patients without CK measurement during treatment had normal CK because of shorter treatment duration, less dialysis, seizure, and surgery in this group. The issue of antibiotic doses is a critical one in the era of antibiotic resistance. Updated guidelines for infectious diseases advocate optimizing antibiotic pharmacokinetics and pharmacodynamics for better outcome.[@b17-tcrm-14-493],[@b18-tcrm-14-493] A trend toward the use of higher doses over time was observed.[@b16-tcrm-14-493] We defined daptomycin dose ≥9 mg/kg as the high-dose therapy based on the finding of a previous study conducted at our hospital system.[@b4-tcrm-14-493] We found that patients with CK elevation received higher doses of daptomycin than those with no documented CK elevation and a significantly higher rate of CK elevation in the high-dose group than that in the standard-dose group. In addition, the difference remained significant when the patients without records of CK levels were excluded (16.0% vs 2.4%, *P*=0.025). Although the number of events was small, we observed a trend of decreasing rate of CK elevation as the dosing frequency decreased: 7.7% (1/13) for once daily, 3.9% (5/129) for once every 48 h, and 0.0% for thrice weekly. The result was not statistically significant (*P*=0.52), but it was consistent with the finding of a previous study reporting more frequent dosing led to increased muscle toxicity.[@b11-tcrm-14-493] Use of high-dose daptomycin in patients with renal impairment is still a concern, and the dosing frequency should be included for clinical consideration.[@b7-tcrm-14-493]

Obese patients in our study received relatively lower doses of daptomycin per kg of body weight. Renal clearance of daptomycin is reduced in obese patients, and they have been identified as a high-risk population for CK elevation.[@b19-tcrm-14-493] The prescribing information recommends to use total body weight for daptomycin dosing, and no dosage adjustment is warranted in obese subjects. While most available studies used the recommended dose of 4--6 mg/kg in obese patients,[@b20-tcrm-14-493] the safety of high-dose daptomycin in this patient group had not been examined. In the present study, 70% of the obese patients received 500 mg of daptomycin, which was the dose supplied in each single-dose vial, resulting in the relatively lower doses than that in the other patients in this study. The efficacy and safety of daptomycin in obese patients with renal impairment need to be carefully evaluated to establish an appropriate dosing regimen for this population.

Lower treatment success rates of daptomycin in treating bloodstream infections were found in our study as compared with a large-scale study by Seaton et al reporting success rates of 78.1% for MRSA and 68.8% for VRE.[@b16-tcrm-14-493] This is partly because, in our hospital, daptomycin is reserved for rescue therapy after first-line treatment failed. Also, more than half of our patients (65.2%) were admitted to the ICU and had multiple organ failures. Therefore, the higher disease severity has likely contributed to the lower treatment success rates in our study.

Limitations
-----------

The most important limitation of the present study is the retrospective nature of the study design, which prevented a delineation of the causality of CK elevation. Also, the serum concentrations of daptomycin were unavailable for risk evaluation. In addition, we cannot address the risk of CK elevation in the patients without renal impairment, who were treated with high doses of daptomycin. Although the rate of CK monitoring in our study was greater than previous studies, 34.1% of our patients did not have CK level for assessment. This may lead to an underestimation of the real incidence of CK elevation.

Conclusion
==========

Our study revealed that compared with standard doses, high-dose daptomycin therapy was associated with a significantly higher rate of CK elevation in patients with severe renal impairment. When increasing the doses of daptomycin to optimize its pharmacokinetic and pharmacodynamic effects, more frequent CK monitoring is highly recommended in this fragile population.
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###### 

Demographic characteristics of patients with renal impairment who received daptomycin therapy

  Demographic characteristics                                                   All patients, N=164       High dose, N=37 (≥9 mg/kg)   Standard dose, N=127 (\<9 mg/kg)   *P*-value
  ----------------------------------------------------------------------------- ------------------------- ---------------------------- ---------------------------------- -----------
  Male                                                                          87 (53.0)                 20 (54.1)                    67 (52.8)                          0.889
  Age (years), range                                                            68.1±16.5 (19.8--93.9)    68.3±15.5                    68.0±16.8                          0.937
  Elderly ≥65 years old                                                         102 (62.2)                24 (64.9)                    78 (61.4)                          0.704
  ICU admission                                                                 107 (65.2)                23 (62.2)                    84 (66.1)                          0.655
  Mean body weight (kg)                                                         58.5±11.9 (36.3--103.1)   53.2±10.2                    60.0±12.0                          \<0.001
  Obesity (BMI \>30)[a](#tfn2-tcrm-14-493){ref-type="table-fn"}                 10 (6.1)                  1 (2.7)                      9 (7.4)                            0.459
  Types of renal failure                                                                                                                                                  
   CL~Cr~ \<30 mL/min                                                           27 (16.5)                 6 (16.2)                     21 (16.5)                          0.963
   Dialysis (iHD/SLED/PD)                                                       101 (61.6)                25 (67.6)                    76 (59.8)                          0.395
   CRRT                                                                         13 (7.9)                  0 (0.0)                      13 (10.2)                          0.042
   AKI                                                                          23 (14.0)                 6 (16.2)                     17 (13.4)                          0.663
  Mean dose (mg/kg)                                                             8.0±2.3                   10.8±2.5                     7.1±1.4                            \<0.001
  Duration (days), median (IQR)                                                 12.5 (11)                 13 (11)                      12 (11)                            0.343
  Type of infections                                                                                                                                                      
   Bloodstream infection                                                        91 (55.5)                 27 (73.0)                    64 (50.4)                          0.015
   Skin and soft tissue infection                                               17 (10.4)                 0 (0.0)                      17 (13.4)                          0.014
   Urinary tract infection                                                      21 (12.8)                 2 (5.4)                      19 (15.0)                          0.166
   Infective endocarditis                                                       4 (2.4)                   1 (2.7)                      3 (2.4)                            1.000
   Septic arthritis                                                             5 (3.0)                   1 (2.7)                      4 (3.1)                            1.000
   Intra-abdominal infection                                                    17 (10.4)                 5 (13.5)                     12 (9.4)                           0.540
   Empirical use                                                                9 (5.5)                   2 (5.4)                      7 (5.5)                            1.000
  Dose frequency                                                                                                                                                          
   QD                                                                           13 (7.9)                  6 (16.2)                     7 (5.5)                            0.076
   QOD                                                                          129 (78.7)                29 (78.4)                    100 (78.7)                         0.962
   TIW                                                                          22 (13.4)                 2 (5.4)                      20 (15.7)                          0.168
  Creatine kinase follow-up                                                     108 (65.9)                25 (67.6)                    83 (65.4)                          0.803
  Number of CK follow-ups per week[b](#tfn3-tcrm-14-493){ref-type="table-fn"}   0.8±1.2                   0.7±0.8                      0.8±1.3                            0.946
  Prior antibiotic use                                                          105 (64.0)                30 (81.1)                    75 (59.1)                          0.014
  Seizure or surgery during therapy                                             28 (17.1)                 6 (16.2)                     22 (17.3)                          0.875
  Concurrent drug[c](#tfn4-tcrm-14-493){ref-type="table-fn"}                    15 (9.1)                  3 (8.1)                      12 (9.4)                           1.000
  Concurrent antibiotic therapy                                                 132 (80.5)                32 (86.5)                    100 (78.7)                         0.295
   β-Lactams                                                                    128 (78.0)                31 (83.8)                    97 (76.3)                          0.338
   Gentamicin                                                                   3 (1.8)                   1 (2.7)                      2 (1.6)                            0.538
   Rifampin                                                                     12 (7.3)                  6 (16.2)                     6 (4.7)                            0.029
   Co-trimoxazole                                                               12 (7.3)                  6 (16.2)                     6 (4.7)                            0.029

**Notes:** Data are presented as number (%) or mean±SD (range) unless stated otherwise.

BMI was available in 158 patients;

Calculated by the number of CK measurement/duration (days) ×7;

Statins, fibrate, or colchicine.

**Abbreviations:** AKI, acute kidney injury; BMI, body mass index; CK, creatine kinase; CL~Cr~, creatinine clearance; CRRT, continuous renal replacement therapy; ICU, intensive care unit; iHD, intermittent hemodialysis; IQR, interquartile range; PD, peritoneal dialysis; QD, every 24 h; QOD, every 48 h; SLED, sustained low-efficiency dialysis; TIW, thrice per week.

###### 

Characteristics of the patients who had creatine kinase elevation

  Patient   Age (years)/sex   Renal failure   Indication (microbe)                 Dose (mg/kg)   Dosing frequency   Treatment duration (days)   CK level (U/L)   Muscle symptoms   Action            Recovery          
  --------- ----------------- --------------- ------------------------------------ -------------- ------------------ --------------------------- ---------------- ----------------- ----------------- ----------------- -----
  1         74.9/F            CKD             Bacteremia (MRSA)                    10.7           QOD                21                          15               2,895             Nil               Stop              Yes
  2         55/M              SLED            Bacteremia (VRE)                     7.6            QOD                8                           53               2,801             NA                Stop              Yes
  3         36.7/M            iHD             Bacteremia (MRSA)                    9.8            QOD                31                          --               1,449             NA                Closely monitor   Yes
  4         78.4/F            iHD             Empirical therapy (−)                9.3            QOD                11                          10               1,939             Muscle soreness   Stop              Yes
  5         38.9/F            AKI             Skin and soft tissue infection (−)   8.3            QOD                13                          23               4,697             Muscle soreness   Stop              Yes
  6         76.6/F            AKI             Septic arthritis (−)                 10.2           QD                 7                           23               1,299             Myalgia           Stop              Yes

**Abbreviations:** AKI, acute kidney injury; CK, creatine kinase; CKD, chronic kidney disease; iHD, intermittent hemodialysis; MRSA, methicillin-resistant *Staphylococcus aureus*; NA, not available, because of intubation and poor consciousness; QD, every 24 h; QOD, every 48 h; SLED, sustained low-efficiency dialysis; VRE, vancomycin-resistant enterococci.

###### 

Possible factors contributing to creatine kinase elevation

  Variables                                                     Elevation of creatine kinase level, N (%)   *P*-value   
  ------------------------------------------------------------- ------------------------------------------- ----------- -------
  Dosage (mg/kg)                                                                                                        0.024
   ≥9                                                           33 (89.2)                                   4 (10.8)    
   \<9                                                          125 (98.4)                                  2 (1.6)     
  Dosing frequency                                                                                                      0.484
   QD                                                           12 (92.3)                                   1 (7.7)     
   QOD                                                          124 (96.1)                                  5 (3.9)     
   TIW                                                          22 (100)                                    0 (0.0)     
  Concurrent drugs[a](#tfn7-tcrm-14-493){ref-type="table-fn"}                                                           0.443
   Yes                                                          14 (93.3)                                   1 (6.7)     
   No                                                           144 (96.6)                                  5 (3.4)     

**Note:**

Statin, fibrate, or colchicine.

**Abbreviations:** QD, every 24 h; QOD, every 48 h; TIW, thrice per week.

###### 

Demographic characteristics of patients with and without CK measurement

  Demographic characteristics                                      CK unavailable, N=56   CK available, N=108   *P*-value
  ---------------------------------------------------------------- ---------------------- --------------------- -----------
  Male                                                             30 (53.6)              57 (52.8)             0.923
  Age (years), range                                               66.3±16.2              69.0±16.6             0.305
  Elderly ≥65 years old                                            31 (55.4)              71 (65.7)             0.193
  ICU admission                                                    36 (64.3)              71 (65.7)             0.853
  Mean body weight (kg)                                            58.6±12.2              58.5±11.9             0.983
  Obesity (BMI \>30)[a](#tfn10-tcrm-14-493){ref-type="table-fn"}   4 (7.1)                6 (5.6)               0.736
  Types of renal failure                                                                                        
   CL~Cr~ \<30 mL/min                                              15 (26.8)              12 (11.1)             0.010
   Dialysis (iHD/SLED/PD)                                          26 (46.4)              75 (69.4)             0.004
   CRRT                                                            6 (10.7)               7 (6.5)               0.370
   AKI                                                             9 (16.1)               14 (13.0)             0.587
  Mean dose (mg/kg)                                                8.0±2.9                7.9±1.9               0.611
  Duration (days), median (IQR)                                    7 (6)                  15 (13.75)            0.001
  Dose frequency                                                                                                
   QD                                                              7 (12.5)               6 (5.6)               0.135
   QOD                                                             43 (76.8)              86 (79.6)             0.673
   TIW                                                             6 (10.7)               16 (14.8)             0.465
  High dose (≥9 mg/kg)                                             12 (21.4)              25 (23.1)             0.803
  Prior antibiotic use                                             35 (62.5)              70 (64.8)             0.770
  Seizure or surgery during therapy                                5 (8.9)                23 (21.3)             0.046
  Concurrent drug[b](#tfn11-tcrm-14-493){ref-type="table-fn"}      8 (14.3)               7 (6.5)               0.100
  Concurrent antibiotic therapy                                    44 (78.6)              88 (81.5)             0.656
   β-Lactams                                                       42 (75.0)              86 (79.6)             0.497
   Gentamicin                                                      3 (5.4)                0 (0.0)               0.038
   Rifampin                                                        5 (8.9)                7 (6.5)               0.546
   Co-trimoxazole                                                  2 (3.6)                10 (9.3)              0.224

**Notes:** Data are presented as number (%) or mean±SD (range) unless stated otherwise.

BMI was available in 158 patients;

Statins, fibrate, or colchicine.

**Abbreviations:** AKI, acute kidney injury; BMI, body mass index; CK, creatine kinase; CL~Cr~, creatinine clearance; CRRT, continuous renal replacement therapy; ICU, intensive care unit; iHD, intermittent hemodialysis; IQR, interquartile range; PD, peritoneal dialysis; QD, every 24 h; QOD, every 48 h; SLED, sustained low efficiency dialysis; TIW, thrice per week.
